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Abstract
Genetic diseases are a major cause of neonatal morbidity and mortality. The clinical
differential diagnosis in severely ill neonates, especially in premature infants, is
challenging. Next generation sequencing (NGS) diagnostics is a valuable tool, but the
turnaround time is often too long to provide a diagnosis in the time needed for
clinical guidance in newborn intensive care units (NICU). To minimize turnaround
time, we developed an ultra-rapid whole genome sequencing pipeline and tested it in
clinical practice. Our pilot case, was a preterm infant presenting with several crises of
dehydration, hypoglycaemia and hyponatremia together with nephrocalcinosis and
hypertrophic cardiomyopathy. Whole genome sequencing was performed using a
paired-end 2x75bp protocol. Sequencing data were exported after 50 sequencing
cycles for a first analysis. After run completion, the rapid-sequencing protocol, a
second analysis of the 2 x 75 paired-end run was performed. Both analyses com-
prised read-mapping and SNP−/indel calling on an on-site Edico Genome DRAGEN
server, followed by functional annotation and pathogenicity prediction using
in-house scripts. After the first analysis within 17 h, the emergency ultra-rapid proto-
col identified two novel compound heterozygous variants in the insulin receptor gene
(INSR), pathogenic variants in which cause Donohue Syndrome. The genetic diagnosis
could be confirmed by detection of hyperinsulinism and patient care adjusted. Non-
etheless, we decided to pursue RNA studies, proving the functional effect of the
novel splice variant and reduced expression levels of INSR in patients skin fibroblasts.
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1 | INTRODUCTION
Genetic diseases are a major contributor to neonatal morbidity and
mortality (Malam et al., 2017; Weiner, Sharma, Lantos, & Kilbride, 2011).
The clinical differential diagnosis in severely ill neonates, particularly
in premature infants, is extremely challenging (Pettinger et al., 2019)
because diagnostic hallmarks of phenotypes are often not yet
completely developed or could be masked by common illnesses in
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preterm neonates (Broekaert et al., 2018; Elliott et al., 2019; Kuehne
et al., 2019). Even if the patients present with a distinct phenotype,
genetic heterogeneity is frequent and makes a candidate gene
approach difficult. Routine metabolic and conventional genetic diag-
nostics, such as karyotyping, Array-based Comparative Genomic
Hybridization (Array-CGH) or single gene sequencing, may take sev-
eral weeks or months and a significant amount of cases remain
unsolved (Malam et al., 2017). Consequently, many patients with
genetic disorders are discharged or die prior to diagnosis (Elliott
et al., 2019).
Next generation sequencing (NGS) studies have led to a break-
through in the identification of a great number of disease genes and
become a part in clinical routine diagnostics in rare disease and/or dis-
ease entities with underlying genetic heterogeneity (Bamborschke
et al., 2018; Boycott et al., 2017; Fakhro et al., 2019; Pergande
et al., 2020). Noteworthy, several pilot studies have been performed
F IGURE 1 Ultra rapid whole-genome sequencing pipeline. After DNA isolation and library preparation, WGS was performed. Alignment and
variant calling were performed on the DRAGEN system and the Cologne Center for Genomics' VARBANK pipeline v.2.12 was used for
annotation and pathogenicity prediction. Using preliminary exported data, we reached a genetic diagnosis already after 17 h [Color figure can be
viewed at wileyonlinelibrary.com]
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over the last 8 years regarding the implementation of NGS in pediatric
and newborn intensive care units (PICU/NICU), because in this setting
an early genomic diagnosis can lead clinicians in management deci-
sions and alter clinical outcome (Kingsmore et al., 2019; Malam
et al., 2017; Meng et al., 2017; Stark et al., 2016). By improving
sequencing techniques, computational data processing and variant
analysis, the mean turnaround time has been shortened to 5–12 days,
though multiple patients have been diagnosed significantly more
rapidly than these mean timeframes, especially if sample transporta-
tion time was minimized by conducting sequencing on-site (Brunelli
et al., 2019; Clark et al., 2019; Elliott et al., 2019; Farnaes et al., 2018;
Kingsmore et al., 2019; Petrikin et al., 2018; Sanford, Wong,
Ellsworth, Ingulli, & Kingsmore, 2020; Saunders et al., 2012; Stark
et al., 2016; Stark et al., 2018). Despite all successes and multiple
cases that have been solved more quickly, results in approximately
1 to 2 weeks remains too long in many cases to have an immediate
impact on clinical care in the short critical time frame of newborn
intensive care units (NICU). Here we present an ultra-rapid whole
genome sequencing pipeline, which we tested successfully in a severe
ill preterm infant and could reach the diagnosis within only 17 h.
2 | MATERIAL AND METHODS
After informed consent, peripheral venous blood was drawn from the
index patient and both parents, immediately transferred to the lab,
and processed according to our ultra-rapid whole-genome sequencing
(WGS) pipeline (Figure 1). Genomic DNA was extracted via QIAamp
DNA Blood Mini Kit (Quiagen, Venlo, Neatherlands) following the
manufacturers' protocol. Library preparation for the index patient was
performed with the Nextrera DNA Flex Kit (Illumina, San Diego, Cali-
fornia) followed by whole genome sequencing on three lanes of the
Illumina HiSeq 4,000 sequencing instrument using a 2x75bp protocol.
For early preliminary results, sequencing data were exported after
50 sequencing cycles for a first analysis. After run completion, a sec-
ond analysis of the 2x75 paired-end run was performed. Alignment
and variant calling were done on an onsite Edico Genome (now part
of Illumina) DRAGEN system and the Cologne Center for Genomics'
VARBANK pipeline v.2.12 (https://varbank.ccg.uni-koeln.de/) was
used for annotation and pathogenicity prediction, as described
(Pergande et al., 2020; Wang et al., 2017). The analysis was restricted
to the target regions of the Agilent SureSelect Human All Exon V6
exome sequencing kit (Agilent, Santa Clara, California). Common vari-
ants with an allele frequency of >0.1% in 1000 Genomes (www.
internationalgenome.org) and deep intronic variants were excluded, as
well as variants annotated frequently in our in-house database as
indication of a pipeline artifact. The remaining variants were then
manually curated by gene function, known disease association and
severity of the predicted effect on the protein product using the
ensemble variant effect predictor (www.ensembl.org). In the first step
we perform an analysis and pathogenicity prediction of each variant.
In the second step these variants are evaluated in combination with
the reported phenotype. By this approach, compared to clinical panel
testing new phenotype associations or expansions of the phenotype
of known-disease causing genes could be ascertained and variants
causing atypical phenotypes are more unlikely to be missed. In known
disease genes, the classification of the American College of Medical
Genetics and Genomics (ACMG) (Richards et al., 2015) and the
recently introduced two-dimensional system for variant classification
of the European Society of Human Genetics (ESHG) (https://www.
eshg.org/index.php?id=949) were applied. For the main resulting vari-
ants primer were designed and ordered overnight. Confirmation of
the variants was performed the following day by Sanger Sequencing
of the index patient and its parents.
2.1 | mRNA analysis
RNA from cultured patient skin fibroblasts was isolated and purified
using the Qiagen RNeasy mini kit including DNase digestion,
according to the kit protocol. cDNA was synthesized from 500 ng of
RNA with random hexamers and SuperScript III reverse transcriptase
(Thermo Fisher Scientific, Waltham, Massachusetts) according to the
manufacturer’s instructions. To evaluate the effect of the c.101-2A>G
variant on splicing, RT-PCR was performed with a pair of primers
spanning exon 2 (F-GCCTCCGCTCAGTATTTGTAGC, R- CAGT
CCTGGAAGTGGTAGTACG) (Figure 2). PCR products were separated
by agarose gel electrophoresis, extracted from gel with NucleoSpin
PCR-cleanup Kit (Macherey-Nagel, Dueren, Germany) and subse-
quently Sanger sequenced. In addition, expression profiling via
RTq-PCR was performed using the primers specific to exon 12–13
(F-GCTGATGACATTGTTGGCCC, R-CTGTAGTTCCCCGGTGACAG)
of the INSR gene. GAPDH was used as a housekeeping gene. The
qPCR reactions were carried out via GoTaq qPCR Master Mix
(Promega, Fichtburg, Wisconsin) in duplicated reactions. Additionally,
we used Log10 serial dilutions as an internal control of our PCR reac-
tions. The relative fold change of the samples was calculated with the
2-ΔΔCT-method. The statistical comparison between control and patient
fibroblast INSR expression was performed via Mann–Whitney U test.
3 | RESULTS
3.1 | Case presentation
Our patient was the second child of nonconsanguineous parents. At
25 weeks of gestation intrauterine growth retardation (IUGR) was
diagnosed; the ultrasound was otherwise unremarkable. No prenatal
genetic testing had been performed. Due to progressive IUGR, the
male infant was delivered via Caesarean section at 31 + 5 weeks of
gestation (birth weight: 752 g [<third centile], body length: 35 cm
[<third centile], head circumference: 26,5 cm [third centile]). The neo-
nate adapted well after delivery (APGAR 4/7/8) and was admitted to
the NICU with spontaneous breathing under noninvasive ventilation
(DuoPAP). Weaning from respiratory support was successful after
11 days. Massive hypertrophic cardiomyopathy with significant LVOT
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obstruction was diagnosed on routine postnatal echocardiography
and treatment with bisoprolol was initiated. The male infant
developed hypo-regenerative anemia, which was treated with blood
transfusions and consecutive EPO and Ferrum supplementation.
L-Thyroxin supplementation was started after routine testing revealed
hypothyroidism (fT3: 1.4 ng/L, fT4: 6.0 ng/L, TSH: 1.02 mU/L). From
the second week of life, incomplete renal Fanconi syndrome devel-
oped, resulting in sodium, potassium, calcium and chloride wasting,
leading to hyponatraemia and hypokalaemia without alkalosis and
renal excretion of amino acids. Ultrasound of head and abdomen were
normal, apart from a nephrocalcinosis type 2b without other alter-
ations of the urinary tract. Oral feeding was able to be successfully
started over the first 2 weeks of life. Despite this, several attempts to
reduce parenteral electrolyte and glucose substitution failed because
of dehydration and unstable blood glucose levels as well as hyp-
onatremia and hypokalaemia.
Apart from low carnitine, extensive metabolic investigations
including German Newborn Screening (http://www.screening-dgns.
de) and a karyotype did not identify the cause of the underlying dis-
ease. Thus, at the age of 2 months, our genetics laboratory was con-
tacted by the neonatal intensive care unit and after counseling and
parental consent, ultra-rapid whole genome sequencing was per-
formed (Figure 1). This led to the identification of two compound het-
erozygous pathogenic variants in the gene encoding the insulin
receptor. Consecutive laboratory testing revealed hyperinsulinism
(Insulin: >1,000 mU/L, C-peptide: 33.6 μg/L) and low levels of insulin
like growth factor 1 (IGF-1:6 μg/L [74–316]) in accordance with the
genetic diagnosis of an insulin receptor defect.
After diagnosis, continuous nasogastric tube feeding with breast
milk led to rapid stabilization and the patient could be discharged to
ambulatory care at the age of 14 weeks. Metformin therapy (25 mg/
kg/d) did not show a significant effect on blood glucoses or insulin
level.
At the age of 6 months, the boy presented with gross haematuria,
haematochezia and skin bleeding. Lab results showed a massively
reduced INR (<0.1), supposedly as a result of liver failure. After fresh
plasma administration and substitution of vitamin K INR normalized
and the bleeding symptoms were successfully stopped. On clinical
follow-up, the boy was admitted to hospital two times due to epi-
sodes of dehydration, electrolyte alterations and hypoglycaemia in the
course of respiratory infections. Unfortunately, he passed away at the
age of 8 months due to a severe bronchopneumonia.
3.2 | Ultra-rapid whole genome sequencing
Sequencing reads were mapped to the hg19 human reference genome
and subsequent analysis was restricted to the target regions of the
Agilent SureSelect Human All Exon V6 exome sequencing kit to focus
on coding and splice site variants.
The firstly exported 50 bp single-end data amounted to 328 mil-
lion mapped unique sequences yielding a mean coverage of 8 and 10x
coverage for 43% of the target sequences, whereas the final paired-
end data led to a significantly higher mean coverage of 34, and 10x
coverage for 90.2% of target regions. Even with data from the first
single-end analysis we were able to diagnose Donohue Syndrome
after 17 h. The full rapid-sequencing protocol, take approximately
45 h, would also have provided a very efficient diagnosis.
After quality filtering, the first single-end dataset resulted in
20 rare single nucleotide variants, which were further evaluated by
F IGURE 2 Confirmation of the INSR variants. (a) The two novel variants were confirmed by Sanger sequencing of the index patient and both
parents and shown to be of compound heterozygous state. (b) Agarose gel of RT-PCR with Sanger sequencing of gel purified RT-PCR amplicons
(blue arrows = primer position) showing skipping of Exon 2 in the patient. (c) RT-qPCR with an intron spanning primer set specific to exon 12–13
showing reduced expression of correctly spliced transcript in the patient (p = .01) [Color figure can be viewed at wileyonlinelibrary.com]
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the investigators. This led to the identification of two novel compound
heterozygous variants in the insulin receptor gene (INSR, OMIM:
147670, RefSeq NM_000208.2) (Figure 2). The first variant was a
novel missense variant in Exon 7 (c.1567G>A; p.D523N). The second
variant was a novel essential splice-site variant in the first intron
(c.101-2A>G) leading to skipping of exon 2 (Figure 2(a),(b)). Both vari-
ants had not been reported in any database and were predicted to be
deleterious by multiple in silico tools (SIFT, PolyPhen, CADD). They
were classified as pathogenic (c.101-2A>G: PVS1, PM2, PM3, PP2,
PP3) and likely pathogenic (c.1567G>A: PM2, PM3, PP2, PP3)
according to the ACMG classification, respectively. The ESHG score
classified both variants as pathogenic (c.101-2A>G: ESHG score
5 + 5; c.1567G>A: ESHG score 4 + 5). The variants were confirmed by
Sanger Sequencing, and shown to co-segregate in the parents in a
compound heterozygous pattern. We further performed functional
work-up with qPCR analysis for the INSR gene showing a significant
decrease in the mRNA expression level comparing the controls
(p = .01) (Figure 2(c)). Of note, the qPCR analysis was not required for
the definitive diagnosis.
4 | DISCUSSION
Recently, several rapid NGS (rNGS) pipelines have been published and
evaluated in larger cohorts focusing on technical and computational
optimization (Brunelli et al., 2019; Clark et al., 2019; Elliott
et al., 2019; Kingsmore et al., 2019; Petrikin et al., 2018; Stark
et al., 2018). Stannenheim et al. introduced the idea of pulsed whole
genome sequence data analysis, but this innovative idea has not been
implemented in recent rNGS protocols (Stranneheim et al., 2014). So
far, the fastest time to NGS aided diagnosis was reported by Clark
et al. using the newest generation of NovaSeq 6,000 sequencers and
automated variant analysis, reaching a median time to genetic diagno-
sis of 20 h and 10 min (Clark et al., 2019). Here, we present an ultra-
rapid WGS pipeline based on the analysis of preliminary data from an
early stage of the sequencing process and successfully applied it in a
critical preterm infant as an individual pilot. We show that skilled man-
ual variant filtering by clinical experts after state-of-the-art variant
annotation may lead even in low coverage data to a clinically convinc-
ing preliminary diagnosis, which was achieved after 17 h for the
patient described here. In combination with the newest generation of
sequencing techniques and automated variant analysis, as described
recently by the group of Kingsmore et al., our approach has the poten-
tial to provide genetic diagnosis within a few hours after collection of
the sample (Clark et al., 2019; Kingsmore et al., 2019). Although there
are some limitations of our ultra-rapid protocol, since other genes
might not be sufficiently covered after the first 50 bp sequencing. We
mention here that our full rapid-sequencing protocol would provide a
state-of-art covered genome within 45 h only.
Homozygous or compound-heterozygous mutations of the insulin
receptor (INSR) gene cause insulin resistance leading to a broad clinical
spectrum. Donohue syndrome (1 per 4,000,000 births) represents the
most severe phenotype related to this gene. Patients present with
intra- and extrauterine growth retardation, fasting hypoglycaemia and
postprandial hyperglycaemia (Kirkwood, Stuart, & Harding, 2018).
Additional features are dysmorphic facial features, acanthosis
nigricans, decreased subcutaneous fat, muscle wasting, cardiomyopa-
thy and nephrocalcinosis (Kirkwood et al., 2018; Simpkin et al., 2014).
Our patient presented with a few of the classical features of Donohue
syndrome like growth retardation, low subcutaneous fat and alter-
ations of blood glucose and electrolytes. Despite this, he could not be
diagnosed clinically in time even by experienced neonatologists and
pediatricians as well as clinical geneticists. Cases like this are experi-
enced by many clinicians even in tertiary care or university hospitals
because these clinical features and problems are difficult to distin-
guish from common complications in preterm newborns. Other typical
features like hypertrichosis or acanthosis nigricans were not present
in our patient. The fact that our ultra-rapid emergency genome pipe-
line for rare disorders provided the diagnosis within 17 h shows again
the power of rNGS in severely ill newborns, because the disease phe-
notypes are often not completely developed or can be masked by
common issues of term and especially preterm neonates (Farnaes
et al., 2018; Kingsmore et al., 2019; Pettinger et al., 2019).
Treatment options are very limited in Donohue syndrome; none-
theless, early diagnosis guides clinicians in counseling of parents and
establishing palliative care according to their needs. In general, stable
blood glucoses can be achieved by continuous enteral nutrition or
parenteral glucose therapy (Kirel et al., 2017; Semple, Williams, &
Dunger, 2010). Metformin has been described having positive effects
on blood glucose and hyperinsulinism in patients with INSR variants
leading to a less severe phenotype, while the effect in Donohue syn-
drome is unclear (Kirel et al., 2017; Semple et al., 2010). In our patient,
stable blood glucoses and transfer to ambulatory care, which was the
main desire of the family, was achieved by continuous nasogastric
feeding. Additional Metformin therapy did not show any effect on
blood glucose or insulin level. On follow-up, our patient presented
with reduced INR and hemorrhage, supposedly as a result of liver fail-
ure in the course of the main disease. The relation of these findings to
a potential side effect of Metformin was considered, and the therapy
terminated. There are only a small number of case studies available on
IGF-1 therapy in patients with Donohue syndrome, and these do not
provide evidence for a conclusive effect on survival (Hovnik
et al., 2013; Kirel et al., 2017; Kirkwood et al., 2018). Most cases of
Donohue syndrome harbor two loss of function variants in the insulin
receptor. Our RNA analysis could prove the truncating effect of the
splice variant but also that remained expression of the normal length
transcript harboring the missense variant. Thus, our patient might
have had a minimal remaining function of the insulin receptor and in
retrospect, a therapeutic trial with high doses of insulin analogs could
have had an additional benefit for the patient. In our particular case,
the parents decided against a therapeutic trial.
Several studies have shown a positive impact of early genomic
diagnosis on patient counseling and treatment outcomes (Farnaes
et al., 2018; Gubbels et al., 2020; Lunke et al., 2020; Meng
et al., 2017). Timely genetic diagnoses have led to management
changes including shift to palliative care, medication changes,
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involvement of additional specialties, and the consideration of new
experimental therapies (Gubbels et al., 2020; Lunke et al., 2020). Fur-
thermore, by improving care and avoiding unnecessary diagnostics,
procedures and medication, rNGS in the NICU has been shown to be
cost-effective and even to reduce the health care costs per patient
(Farnaes et al., 2018; Stark et al., 2018). Despite all the proven posi-
tive impact, with the recent breakthroughs in gene therapy of rare
genetic disease as well as enzyme substitution in congenital metabolic
diseases, the optimal benefit from rapid NGS diagnostics requires fur-
ther minimization of time from onset of symptoms to the initiation of
an effective treatment. In these situations, even a few hours could
make the decisive difference, as illustrated by a recent case of molyb-
denum cofactor deficiency reported by Kingsmore et al.(Kingsmore
et al., 2020). In our case, the genetic diagnosis had a direct impact on
clinical care leading to rapid transfer to ambulatory care. An earlier
diagnosis would additionally have saved several weeks of intensive
care treatment and parenteral nutrition.
While most published studies focused on technical improvements
of the sequencing pipeline and variant interpretation, Lunke et al.
tested the clinical feasibility of ultra-rapid NGS in critically ill infants in
the Australian Public Health Care System. Under these conditions
they reported a mean time from sample receipt to ultra-rapid exome
sequencing report of 3.3 days (Lunke et al., 2020). Time from hospital
admission to ultra-rapid exome sequencing report was 17.5 days,
highlighting practical complications such as delay of referral to genetic
counseling, availability of parents for genetic counseling and consent
and sample transportation time. To further minimize the time from
indication and initiation of exome or genome sequencing to the
obtaining of the results for clinical action, one should aim to imple-
ment the ultra-rapid NGS as routine procedure in the tertiary care
NICUs, as demonstrated in our proof-of-principle case. At the
moment this will only be possible in developed countries with a public
funded health care system. But as costs are expected to decrease with
further technical progress and implementation into routine testing, in
a second phase also smaller hospitals and developing countries might
be able to establish emergency sequencing diagnostics. Here, we offer
a protocol, with the first read-out within 17–18 h and a full read-out
of the genome within 45 h (below 2d). The implementation into health
care systems will only be successful if clinicians experience ultra-rapid
NGS as useful in their daily clinical work, with direct impact on patient
treatment decisions and demand it from the payors and others who
can fund this type of work. To support optimal outcomes and experi-
ences, the sequencing technology should be as fast as possible to pro-
vide results as soon as possible. In this context, our ultra-rapid NGS
pipeline will expand the impact and utility by further minimizing
sequencing time, and provides a powerful approach based on the cur-
rently available sequencing technologies.
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